Long-term effects in bone mineral density after different bariatric procedures in patients with type 2 diabetes: outcomes of a randomized clinical trial

dc.contributor.authorGuerrero Pérez, Fernando
dc.contributor.authorCasajoana, Anna
dc.contributor.authorGómez Vaquero, Carmen
dc.contributor.authorVirgili, Núria
dc.contributor.authorLópez Urdiales, Rafael
dc.contributor.authorHernández Montoliu, Laura
dc.contributor.authorPujol Gebelli, Jordi
dc.contributor.authorOsorio, Javier
dc.contributor.authorPrats, Anna
dc.contributor.authorPujol Gebelli, Jordi
dc.contributor.authorPérez Maraver, Manuel
dc.contributor.authorFernández Veledo, Sonia
dc.contributor.authorVendrell, Joan
dc.contributor.authorVilarrasa, Nuria
dc.date.accessioned2020-11-10T12:11:38Z
dc.date.available2020-11-10T12:11:38Z
dc.date.issued2020-06-01
dc.date.updated2020-11-03T17:11:50Z
dc.description.abstractThere is scant evidence of the long-term effects of bariatric surgery on bone mineral density (BMD). We compared BMD changes in patients with severe obesity and type 2 diabetes (T2D) 5 years after randomization to metabolic gastric bypass (mRYGB), sleeve gastrectomy (SG) and greater curvature plication (GCP). We studied the influence of first year gastrointestinal hormone changes on final bone outcomes. Forty-five patients, averaging 49.4 (7.8) years old and body mass index (BMI) 39.4 (1.9) kg/m(2), were included. BMD at lumbar spine (LS) was lower after mRYGB compared to SG and GCP: 0.89 [0.82;0.94] vs. 1.04 [0.91;1.16] vs. 0.99 [0.89;1.12],p= 0.020. A higher percentage of LS osteopenia was present after mRYGB 78.6% vs. 33.3% vs. 50.0%, respectively. BMD reduction was greater in T2D remitters vs. non-remitters. Weight at fifth year predicted BMD changes at the femoral neck (FN) (adjustedR(2): 0.3218;p= 0.002), and type of surgery (mRYGB) and menopause predicted BMD changes at LS (adjustedR(2): 0.2507;p< 0.015). In conclusion, mRYGB produces higher deleterious effects on bone at LS compared to SG and GCP in the long-term. Women in menopause undergoing mRYGB are at highest risk of bone deterioration. Gastrointestinal hormone changes after surgery do not play a major role in BMD outcomes.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid32545353
dc.identifier.urihttps://hdl.handle.net/2445/171943
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm9061830
dc.relation.ispartofJournal of Clinical Medicine, 2020, vol. 9, num. 6
dc.relation.urihttps://doi.org/10.3390/jcm9061830
dc.rightscc by (c) Guerrero Pérez et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationDensitat mineral òssia
dc.subject.classificationCirurgia de l'obesitat
dc.subject.otherBone density
dc.subject.otherObesity surgery
dc.titleLong-term effects in bone mineral density after different bariatric procedures in patients with type 2 diabetes: outcomes of a randomized clinical trial
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Guerrero-PerezF.pdf
Mida:
792.26 KB
Format:
Adobe Portable Document Format